Specialty-drug spending spawns protest

Has spending on specialty drugs hit a wall? Spending on these meds--including those for cancer and multiple sclerosis--is rising at a rapid pace, and that has some payers and watchdogs clamoring for alternatives.

Experts estimate that specialty drug spending could top $99 billion by 2010, nearly double the $54 billion spent in 2006. To curb costs, pharmacy benefits managers already are enforcing rules on drug selection, usage, and dosage. But they fear that's not enough to rein in spending. So they're pushing Congress to make some changes: create a clear pathway for generic biologics, reinforce rules requiring cheaper therapies, and back pay-for-performance projects like the one Johnson & Johnson agreed to in the U.K. to get Velcade on the National Health Service formulary.

- see the item at the WSJ Health Blog
- get more details in the WSJ article

Related Articles:
Can specialty drugs turn pharma tide? Report
Study: Costlier drug worked better. Report
Drug makers jack prices up 7.8%. Report
Specialty drugs emerge as key price driver. Report

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

The role of distributors like AmerisourceBergen, is to ensure patients can get access to therapies, no matter where they present.